Get Quartz in your inbox

Free daily briefing on global business news.

Moderna and Merck's personalized mRNA cancer vaccine cut melanoma recurrence risk by 42%

The therapy, given with Keytruda, cut the risk of distant metastasis or death by 38%, and overall survival data remain immature

Bloomberg / Getty Images

Merck $MRK and Moderna $MRNA reported detailed Phase 3 results showing that their individualized mRNA therapy, intismeran autogene, lowered the chance of relapse or death by 42% when added to Merck's Keytruda. The comparison was with Keytruda alone in patients with completely resected stage IIB-IV melanoma.

The companies said the combination cut the risk of distant metastasis or death by 38% after a median follow-up of 24.6 months. The two-year........

© Quartz